India’s drug regulator’s subject expert committee on COVID-19 will on Friday review the Serum Institute of India’s applications for using Kovovax among people between the ages of two to seven years and seven to 11 years, official sources said. Emergency use authorization has been sought for. The two applications were submitted by Prakash Kumar Singh, director of government and regulatory affairs at the Serum Institute of India (SII), on March 16 and June 1.
The expert panel at its last meeting in April had sought more data from SII after its application seeking emergency use authorization of Kovovax for seven to 11 years. The Drug Controller General of India (DCGI) on December 28 approved Kovovax for restricted use in emergency situations in adults and on March 9 in the age group of 12 to 17 years, subject to certain conditions.
India started immunization of children in the age group of 12-14 on 16 March. The nationwide vaccination campaign was launched on January 16 last year, in which health workers were vaccinated in the first phase. The vaccination of frontline workers started from February 2 last year. The next phase of COVID-19 vaccination began on March 1 last year for people above 60 years of age and 45 years and above with specified co-morbid conditions. India started vaccination for all people above 45 years of age from 1st April last year. Following this, the government decided to expand its vaccination campaign by allowing everyone over the age of 18 to be vaccinated against the viral disease from May 1 last year.
The next phase of vaccination began on January 3 for adolescents in the age group of 15-18 years. India began giving preventive doses of vaccines to health care and frontline workers and people aged 60 years and above from January 10. The country began giving precautionary doses of COVID-19 vaccines to all people over the age of 18 at private immunization centers on April 10.
Read all the latest news, breaking news, watch top videos and watch Live TV right here.